Welcome to our dedicated page for Kalvista Pharm SEC filings (Ticker: KALV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
KalVista Pharmaceuticals SEC filings document 8-K disclosures for a commercial-stage pharmaceutical company focused on oral rare-disease therapies. The filings cover results of operations and financial condition, Regulation FD materials, product-revenue updates tied to EKTERLY, and the company’s Nasdaq-listed common stock.
The filing record also includes governance and compensation disclosures, board committee changes, executive appointments, material definitive agreements, and capital-structure actions. Financing disclosures include the completed sale of 3.250% convertible senior notes due 2031, while other reports describe exhibit filings, furnished press releases, Inline XBRL cover data, and formal disclosure treatment under the Exchange Act.
KalVista Pharmaceuticals insider Form 4: The filing shows Chief Medical Officer Audhya Paul K. received vesting equity and completed a tax-withholding sale. On 08/17/2025 the reporting person was issued 6,446 shares (reported as acquisition via RSU/PSU vesting), bringing beneficial ownership to 119,472 shares. Two RSU entries on 08/17/2025 reflect settlement rights to a total of 6,446 underlying shares at no cash cost. On 08/18/2025 a sale of 2,939 shares occurred at $13.187 per share to satisfy tax withholding, reducing beneficial ownership to 116,533 shares. The sale is described as a routine "sell to cover" for tax obligations.
KalVista Pharmaceuticals (KALV) Chief Executive Officer and Director Benjamin L. Palleiko reported transactions in the company's common stock on August 17-18, 2025. On August 17 he was credited with 9,362 shares as vested restricted/performance stock units; those awards converted into a mix of settled shares and remaining RSU/PSU interests. On August 18 he sold 4,409 shares at $13.187 per share to satisfy tax withholding, leaving beneficial ownership of 374,548 shares of common stock and several outstanding RSU/PSU entitlements.
KalVista Pharmaceuticals insider award disclosure: KalVista reported that Benjamin L. Palleiko, a director and the Chief Executive Officer, received equity awards on 08/11/2025 consisting of 113,920 restricted stock units (RSUs) and an employee stock option covering 113,920 shares with an exercise price of $12.51. The RSUs convert to one share each upon settlement for no consideration, and the RSU vesting schedule provides 1/16th of the RSUs on each quarterly anniversary beginning November 11, 2025, subject to continued service. The option vests over four years beginning September 11, 2025, with 1/48th vesting initially and monthly thereafter, and has an expiration date of 08/10/2035. The reported holdings after these awards are 113,920 RSUs and 113,920 underlying shares from the option, each shown as direct beneficial ownership.
KalVista Pharmaceuticals, Inc. (KALV) – Form 4 insider transaction summary:
- CEO & Director Benjamin L. Palleiko vested 87,500 performance stock units (PSUs) on 07 Jul 2025 after the company met pre-defined performance metrics. Each PSU converted 1:1 into common shares.
- On 09 Jul 2025, Palleiko effected a sale of 32,979 shares at $15.6925 per share. The filing states the sale was solely to satisfy tax-withholding obligations via a “sell-to-cover” mechanism and was not a discretionary trade.
- After the transactions, Palleiko’s direct beneficial ownership stands at 369,595 common shares, a net increase of 54,521 shares versus pre-vesting levels.
The vesting confirms management’s achievement of specified operating or clinical milestones set in January 2023, while the partial sale is procedural. Overall, the filing signals continued insider equity alignment without indicating either bullish or bearish discretionary sentiment.
KalVista Pharmaceuticals (KALV) Form 4: Chief Development Officer Christopher Yea reported two transactions. On 8 July 2025, 60,000 performance stock units (PSUs) vested and converted 1-for-1 into common shares after the company met its performance metrics, raising his direct holdings to 158,189 shares.
On 9 July 2025, Yea executed a Rule 10b5-1 coded S sale of 30,250 shares at an average price of $15.6925 strictly to cover tax-withholding obligations (“sell-to-cover”), leaving him with 127,939 shares.
The net effect is a 29,750-share increase in ownership. No derivative securities were reported. The transactions appear routine and non-discretionary under the company’s equity compensation plan.